
Immunocore Holdings (IMCR) Stock Forecast & Price Target
Immunocore Holdings (IMCR) Analyst Ratings
Bulls say
Immunocore Holdings PLC is positioned favorably due to its pipeline of innovative therapies, particularly the successful early commercial execution of its lead product, KIMMTRAK, which has demonstrated a significant survival benefit in patients with metastatic uveal melanoma (mUM). The company is also advancing clinical activities and potential treatments across various therapeutic areas, with notable expectations for positive outcomes in upcoming clinical readouts, specifically for candidates IMC-F106C and IMC-M113V. The developments in HIV treatment and other clinical programs underscore Immunocore's commitment to cutting-edge immunotherapies, reinforcing its status as a leader in the TCR-based immunotherapy landscape.
Bears say
Immunocore Holdings faces a challenging outlook primarily due to anticipated low clinical benefit from future PRAME readouts, leading to significantly reduced probabilities of success for key candidates like IMC-F106C in the treatment of cancers. The company may struggle to develop additional successful clinical candidates outside its established platforms, compounded by concerns about treatment safety, scalability, and accessibility that are crucial for advancing innovative therapies. Furthermore, the complexities involved in addressing HIV, including the virus's ability to evade immune responses and the exhaustion of T cells, raise significant concerns regarding the effectiveness of their treatment candidates, indicating a more precarious financial trajectory.
This aggregate rating is based on analysts' research of Immunocore Holdings and is not a guaranteed prediction by Public.com or investment advice.
Immunocore Holdings (IMCR) Analyst Forecast & Price Prediction
Start investing in Immunocore Holdings (IMCR)
Order type
Buy in
Order amount
Est. shares
0 shares